Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy
- 1 February 2006
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Hepatology
- Vol. 43 (2), 209-220
- https://doi.org/10.1002/hep.21051
Abstract
No abstract availableThis publication has 127 references indexed in Scilit:
- A Randomized Phase III Study of Doxorubicin Versus Cisplatin/Interferon α-2b/Doxorubicin/Fluorouracil (PIAF) Combination Chemotherapy for Unresectable Hepatocellular CarcinomaJNCI Journal of the National Cancer Institute, 2005
- Use of lamivudine to prevent hepatitis B virus reactivation during chemotherapy in breast cancer patientsBreast Cancer Research and Treatment, 2004
- Transarterial chemo-lipiodolization can reactivate hepatitis B virus replication in patients with hepatocellular carcinomaJournal of Hepatology, 2004
- Catastrophic heparin-induced thrombocytopenia/thrombosis syndrome related to the use of a Port-A-Cath in a breast cancer patient receiving chemotherapySupportive Care in Cancer, 2004
- Reactivation of resolved hepatitis B virus infection after allogeneic haematopoietic stem cell transplantationBone Marrow Transplantation, 2004
- Hepatitis B virus reactivation with clinical flare in allogeneic stem cell transplants with chronic graft-versus-host diseaseBone Marrow Transplantation, 2002
- Lamivudine treatment for reverse seroconversion of hepatitis B 4 years after allogeneic bone marrow transplantationBone Marrow Transplantation, 2002
- Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-upNew England Journal of Medicine, 1995
- Fulminant hepatic failure in non-Hodgkin lymphoma patients treated with chemotherapyEuropean Journal Of Cancer, 1992
- The use of corticosteroids in conjunction with antiviral therapy in chronic hepatitis B with ongoing viral replicationJournal of Hepatology, 1986